Status:
UNKNOWN
Thromboelastography As An Assessment Tool for Possible Clopidogrel and Aspirin Resistance
Lead Sponsor:
Assaf-Harofeh Medical Center
Conditions:
Acute ST SEgment Elevation Myocardial Infarction
Eligibility:
All Genders
18+ years
Phase:
PHASE3
Brief Summary
TEG is an established technique to assess the quality of clot formation' used mainly in surgery and obstetrics to determine possible bleeding diathesis. Recently it became to be used in cardiology, wh...
Detailed Description
TEG system may provide the capabilities needed to deliver personalized therapy, first, because it can identify patients at risk of ischemic event based on hemostatic influences, particularly platelet ...
Eligibility Criteria
Inclusion
- Patients 18 years of age or more
- Patients admitted with acute STEMI as a first Coronary event
- Duration of symptoms less than 12 hours
- PCI elected as a treatment of acute STEMI
- Informed consent signed
Exclusion
- Thrombolytic therapy
- PCI not performed after diagnostic angiography (conservative treatment, CABG)
- DES used in PPCI
- Staged PCI procedures
- Previous clopidogrel treatment at any time for any reason
- Previous myocardial infarction
- Known bleeding diathesis of any kind
- Significant renal insufficiency (GFR\<40 ml/min)
- LFT disturbances (Transaminase elevation more than x3 ULN)
- Significant anemia (Hb\<10) or a need for blood transfusion
- Significant Thrombocytopenia (PLT Count \< 150000)
- Known Clopidogrel allergy
- Known Active peptic disease
Key Trial Info
Start Date :
June 1 2008
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
October 1 2009
Estimated Enrollment :
50 Patients enrolled
Trial Details
Trial ID
NCT00697021
Start Date
June 1 2008
End Date
October 1 2009
Last Update
June 13 2008
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Assaf Harofeh MC ICCU
Zerrifin, Israel, 73000